FDA Approves HIV Drug Dolutegravir for Newborn Infants

Full-term infants weighing at least two kilograms can now receive this medication to help manage HIV-1 exposure.

Updated on Oct. 22, 2026 in Babies

Bold flat-color editorial illustration featuring a glass medicine dropper and a geometric cube, representing pediatric medical dosing standards.
The FDA approved dolutegravir for newborn infants in August 2026, providing a new antiretroviral treatment for babies weighing at least two kilograms. AI Illustration. Upload story photo >

Live Poll

Do you believe medical research developments typically result in improved health outcomes for the general public?

In August 2026, the FDA approved the antiretroviral medication dolutegravir for full-term newborns starting from birth. This expansion of use for infants weighing at least two kilograms provides a new treatment option for babies exposed to HIV-1.

Why it matters

Newborns process medications differently than adults and children, yet they have historically had few approved antiretroviral options. This approval helps fill that gap by providing an evidence-based dosing regimen specifically for infants.

The approval is based on the IMPAACT 2023 Phase I trial, which followed 48 full-term infants across the United States, South Africa, and Thailand for 16 weeks to ensure safety. The study confirmed that a specific dosing regimen achieves appropriate drug levels in newborns.

The players

FDA

The United States agency responsible for regulating medications and protecting public health.

IMPAACT 2023

A Phase I clinical trial that evaluated the safety and dosing of dolutegravir in HIV-1 exposed newborns.

The details

Dolutegravir works as an integrase strand transfer inhibitor, preventing the HIV virus from inserting its DNA into human cells. Because newborns have different metabolic capacities than older children, researchers had to identify a precise dosing strategy to maintain safe and effective drug concentrations. Infants in the trial received either two separate single doses or repeated doses to reach these target levels.

Timeline

  1. August 2026: FDA announced the expanded approval of dolutegravir for newborns.

Health Landscape

The medical field has long struggled with limited data on how to safely dose antiretrovirals for the smallest patients. This approval follows the trajectory of the IMPAACT 2023 trial, which aims to expand the range of safe, effective treatments available for neonates living with HIV.

This development expands the options available to families managing HIV-1 exposure in newborns weighing at least two kilograms. If your child is impacted, talk to your pediatrician or a pediatric infectious disease specialist to discuss whether this treatment is appropriate for their specific care plan.

The takeaway

This approval provides a new clinical pathway for infants exposed to HIV-1 by utilizing a verified dosing protocol for newborns. Caregivers should consult a specialist to review their child's treatment plan and ensure all dosing follows the latest clinical guidelines.

Further reading

For more information on newborn health and development, visit our Babies section.

Live Poll

Do you believe medical research developments typically result in improved health outcomes for the general public?